Amnesia Market

Market Overview:

The 7 major amnesia markets are expected to exhibit a CAGR of 3.92% during 2024-2034.

The amnesia market has been comprehensively analyzed in IMARC's new report titled "Amnesia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Amnesia refers to a condition characterized by partial or complete loss of memory. It is a neurological illness that can affect a person's ability to recall information, events, or personal experiences. There are two main types of this disease: retrograde and anterograde. Retrograde amnesia refers to a decline in memories that were formed before the onset of the condition, while anterograde amnesia involves the inability to create new memories after the commencement of the illness. Some individuals suffering from this ailment may experience a combination of both types. The disorder can vary in severity, ranging from temporary and mild to permanent and profound. Numerous indications associated with this illness include difficulty remembering and learning, confusion, disorientation, false memories, tremors or other uncoordinated movements, etc. The diagnosis of amnesia typically involves a thorough evaluation of the patient's symptoms, medical history, and physical examination. A healthcare provider may also perform neurological or cognitive tests to assess the functioning of the brain and identify any abnormalities that could be causing the underlying disease.

The increasing cases of traumatic brain injuries that can damage specific areas of the brain involved in memory formation and retrieval are primarily driving the amnesia market. In addition to this, the rising prevalence of various risk factors, including stroke, central nervous system infection, substance abuse, brain tumors, stress, neurodegenerative disease, etc., is also creating a positive outlook for the market. Moreover, the inflating application of psychotherapy that involves numerous techniques, such as hypnosis and guided imagery, to access forgotten memories, thereby maintaining independence and functionality in the patient's daily life, is further bolstering the market growth. Apart from this, the widespread adoption of cholinesterase inhibitors, like donepezil, rivastigmine, galantamine, etc., to reduce behavioral symptoms and enhance neurotransmission by increasing the levels of acetylcholine in the brain, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of transcranial magnetic stimulation procedures, owing to their numerous advantages, including activation of targeted brain regions and restoration of dysfunctional neural networks with minimal side effects, is expected to drive the amnesia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the amnesia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for amnesia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the amnesia market in any manner.

Key Highlights:

• Worldwide, the prevalence of transient global amnesia is roughly 2.9–10 per 100,000 people per year.
• The risk of amnesia is greater for older age people above the age of 60.
• Amnesic diseases are identified in around 3.4 out of 100,000 adults aged 50 to 60 each year.
• Amnesia is more prevalent in non-Hispanic Black and older Latino as compared to non-Hispanic Whites.
• Roughly 50% of cases of amnesia result from injury or physical trauma.
• Korsakoff syndrome, a type of amnesia, is associated with alcohol use in about 37% of cases.
• Patients with amnesia spend 20% less time in REM sleep than healthy people.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034 

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the amnesia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the amnesia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current amnesia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the amnesia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the amnesia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the amnesia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of amnesia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amnesia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amnesia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with amnesia across the seven major markets?
• What is the size of the amnesia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of amnesia?
• What will be the growth rate of patients across the seven major markets?

Amnesia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for amnesia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the amnesia market?
• What are the key regulatory events related to the amnesia market?
• What is the structure of clinical trial landscape by status related to the amnesia market?
• What is the structure of clinical trial landscape by phase related to the amnesia market?
• What is the structure of clinical trial landscape by route of administration related to the amnesia market?